Market Analysis
Compliance Is Not Discretionary: BIOSECURE Act Impact Tracker
A policy deadline is driving manufacturing investment that market demand would not have produced.
What the Framework Reveals
Reshoring projects and equipment demand from the BIOSECURE Act
15–20%
of U.S. biologic manufacturing tied to the named contractors (WuXi AppTec, WuXi Biologics, BGI, MGI)
$20–24B
estimated reshoring cost over the Act's full course
90%
of that spend landing in North America
The BIOSECURE Act names WuXi AppTec, WuXi Biologics, BGI, and MGI as companies of concern and bars federally funded entities from using them after compliance deadlines. Industry estimates place 15 to 20 percent of U.S. biologic manufacturing with the named contractors, across 100 to 150 active drug programs. The resulting reshoring is estimated at $20–24B over its full course.
Source: Market Report · Jan 2026 · MKA-47-MA, Executive Summary